Patient and provider-level factors associated with changes in utilization of treatments in response to evidence on ineffectiveness or harm

Laura Barrie Smith, Nihar R. Desai, Bryan Dowd, Alexander Everhart, Jeph Herrin, Lucas Higuera, Molly Moore Jeffery, Anupam B. Jena, Joseph S. Ross, Nilay D. Shah and Pinar Karaca-Mandic ()
Additional contact information
Laura Barrie Smith: University of Minnesota School of Public Health
Nihar R. Desai: Yale School of Medicine
Bryan Dowd: University of Minnesota School of Public Health
Alexander Everhart: University of Minnesota School of Public Health
Jeph Herrin: Yale School of Medicine
Lucas Higuera: Medtronic
Molly Moore Jeffery: Mayo Clinic
Anupam B. Jena: Harvard Medical School
Joseph S. Ross: Yale School of Medicine
Nilay D. Shah: Mayo Clinic
Pinar Karaca-Mandic: National Bureau of Economic Research

International Journal of Health Economics and Management, 2020, vol. 20, issue 3, No 5, 299-317

Abstract: Abstract High-quality health care not only includes timely access to effective new therapies but timely abandonment of therapies when they are found to be ineffective or unsafe. Little is known about changes in use of medications after they are shown to be ineffective or unsafe. In this study, we examine changes in use of two medications: fenofibrate, which was found to be ineffective when used with statins among patients with Type 2 diabetes (ACCORD lipid trial); and dronedarone, which was found to be unsafe in patients with permanent atrial fibrillation (PALLAS trial). We examine the patient and provider characteristics associated with a decline in use of these medications. Using Medicare fee-for-service claims from 2008 to 2013, we identified two cohorts: patients with Type 2 diabetes using statins (7 million patient-quarters), and patients with permanent atrial fibrillation (83 thousand patient-quarters). We used interrupted time-series regression models to identify the patient- and provider-level characteristics associated with changes in medication use after new evidence emerged for each case. After new evidence of ineffectiveness emerged, fenofibrate use declined by 0.01 percentage points per quarter (95% CI − 0.02 to − 0.01) from a baseline of 6.9 percent of all diabetes patients receiving fenofibrate; dronedarone use declined by 0.13 percentage points per quarter (95% CI − 0.15 to − 0.10) from a baseline of 3.8 percent of permanent atrial fibrillation patients receiving dronedarone. For dronedarone, use declined more quickly among patients dually-enrolled in Medicare and Medicaid compared to Medicare-only patients (P

Keywords: De-adoption; Physician behavior; Disparities (search for similar items in EconPapers)
JEL-codes: I10 I11 (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s10754-020-09282-2 Abstract (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:kap:ijhcfe:v:20:y:2020:i:3:d:10.1007_s10754-020-09282-2

Ordering information: This journal article can be ordered from
http://www.springer. ... th/journal/10754/PS2

DOI: 10.1007/s10754-020-09282-2

Access Statistics for this article

International Journal of Health Economics and Management is currently edited by Leemore Dafny, Robert Town, Mark Pauly, David Dranove and Pedro Pita Barros

More articles in International Journal of Health Economics and Management from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().